SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has entered into an agreement to initiate the “first-in-man” clinical study of a medical device to treat the Human Immunodeficiency Virus (HIV) which causes Acquired Immune Deficiency Syndrome (AIDS). The Aethlon Hemopurifier® is a medical device created to provide real-time therapeutic filtration of infectious viruses and immunosuppressive proteins. The Hemopurifier® holds promise to extend the lives of AIDS patients by removing HIV strains that cause drug failure and reducing the presence of viral proteins that kill-off immune cells. The clinical study was approved by the Institutional Ethics Committee at the Jattinder Gambhir Hospital (J.G. Hospital) in Punjab, India and is anticipated to begin in September.
